Highlighting Key Data from the CHERISH and SHINE Studies

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for patients with hereditary angioedema.

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD) is associated with quality-of-life improvements.

Chronic and acute graft-versus-host disease are managed differently, affect different organs, and impact patients in different ways.

Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.

For patients with interstitial lung disease (ILD), a subsequent diagnosis of pulmonary hypertension substantially increases utilization of healthcare resources as well as costs.